Literature DB >> 6740075

Some observations on poliomyelitis lameness surveys.

R H Bernier.   

Abstract

Since 1974, greater than 100 different surveys have been carried out throughout the developing world to estimate the prevalence of lameness due to poliomyelitis. Reported prevalence rates have ranged from less than 1 to a high of 25 per 1,000 children surveyed and have prompted many countries to undertake polio vaccination programs. A review of surveys conducted to date reveals considerable variation in both the choice and use of survey methods and in the assumptions made in the analysis and interpretation of findings. More precise and comparable data about the risk of poliomyelitis could be obtained in future surveys by incorporating a standard case definition, by using house-to-house case-finding methods in representative community-based samples, by analyzing and presenting rates in more clearly defined ways, and by selecting stable populations for study.

Entities:  

Mesh:

Year:  1984        PMID: 6740075     DOI: 10.1093/clinids/6.supplement_2.s371

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

2.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

Review 3.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

Review 4.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.

Authors:  P W Kok; J Leeuwenburg; P Tukei; A L van Wezel; J G Kapsenberg; G van Steenis; A Galazka; S E Robertson; D Robinson
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

6.  Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks.

Authors:  A R Hinman; J P Koplan; W A Orenstein; E W Brink; B M Nkowane
Journal:  Am J Public Health       Date:  1988-03       Impact factor: 9.308

7.  Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-02-18       Impact factor: 3.090

8.  An evaluation of the sensitivity of acute flaccid paralysis surveillance for poliovirus infection in Australia.

Authors:  Rochelle E Watkins; P Anthony J Martin; Heath Kelly; Ben Madin; Charles Watson
Journal:  BMC Infect Dis       Date:  2009-09-30       Impact factor: 3.090

9.  The poliomyelitis story: a scientific hegira.

Authors:  D M Horstmann
Journal:  Yale J Biol Med       Date:  1985 Mar-Apr

10.  Estimating the extent of vaccine-derived poliovirus infection.

Authors:  Alison Wringe; Paul E M Fine; Roland W Sutter; Olen M Kew
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.